CELC Shariah Compliance
Screening Methodology: AAOIFI
NOT HALAL
Last Updated: April 02, 2026
Report Source: 2025 Annual Report
Celcuity Inc. Stock Analysis CELC
Celcuity, Inc. operates as a cellular analysis company. The company is headquartered in Minneapolis, Minnesota and currently employs 155 full-time employees. The company went IPO on 2017-09-20. Its lead therapeutic candidate is gedatolisib, a potent, small-molecule reversible inhibitor that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. Its development programs for gedatolisib focus on the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), or HR+/HER2-, advanced or metastatic breast cancer and patients with metastatic castration resistant prostate cancer. A Phase III clinical trial of VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast has commenced. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells.
Read More Celcuity Inc (CELC) Chart
Key Statistics of Celcuity Inc (CELC)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$130.20Volume
1.48MP/E Ratio (TTM)
-52 Week Range
Market Cap
6.85BAvg. Volume
1.19MDividend Yield
-Financial Metrics & Statements of Celcuity Inc (CELC)
FAQ's for Celcuity Inc (CELC)
- According to Musaffa’s Shariah screening methodology, Celcuity Inc (CELC) is currently classified as NOT HALAL as of April 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.